With over 20 years of experience in clinical research, Brandy Lind is a seasoned leader in project management.  As Vice President of Global Project Management at Rho, Ms. Lind has played a pivotal role in driving the successful execution of complex, multi-phase clinical trials and development programs across a variety of therapeutic areas.  Specifically, she has specialized in asthma, allergic diseases, transplantation, and dermatology programs.

Ms. Lind’s career began with the NIAID/NIH-funded Inner City Asthma Consortium (ICAC), where she supported groundbreaking clinical trials, including studies on anti-IgE therapy and exhaled nitric oxide tests—research that helped shape national asthma guidelines. She has experience in common pulmonary function tests, including spirometry, methacholine challenge, exhaled nitric oxide, and lung volume testing.

Ms. Lind later served as Program Director for the Statistical and Data Coordinating Center of the Immune Tolerance Network (ITN), overseeing more than 30 studies focused on allergy, immunology, and transplantation.  During her tenure with ITN, Ms. Lind worked on the landmark LEAP, or the Learning Early About Peanut Allergy, study which demonstrated that regular peanut consumption (beginning in infancy and continuing through 5 years of age) led to an 81% reduction in the development of peanut allergy in high-risk children.

Ms. Lind has provided expert oversight for a wide range of clinical trials, demonstrating her skill in managing complex portfolios, ensuring adherence to enrollment goals, study timelines, regulatory standards, and budgets.  Her ability to build and lead high-performing project teams has been a hallmark of her career. Ms. Lind is known for her meticulous attention to detail, her capacity to drive results in challenging environments, and her unwavering commitment to quality and compliance. Whether managing a single study or a global portfolio, she ensures that every aspect of the trial is executed with precision, ensuring optimal outcomes for both patients and sponsors.

Why Respiratory?

“When I first started at Rho, I was fortunate to be assigned to the Inner City Asthma Consortium (ICAC), a research consortium that had been working together since 1991. Over the next 5 years, I learned how asthma and allergic disease severely impacts children, especially those living in inner cities. It was an eye-opening experience to travel to the sites and hear the patients talk about how asthma has affected their child’s attendance at school, caused numerous ED visits, and left them with high healthcare bills. This research became important to me because I knew that reducing the number of asthma exacerbations could make a real difference in the lives of these children and their families.”

This is what drives Brandy:

“I want to help patients improve their quality of life, and this drives me to build effective teams and efficient processes so that we can deliver quality results as quickly as possible.”